Impact of anti-CD20 monoclonal antibodies on serologic response to
Por um escritor misterioso
Descrição
Imaging the mechanisms of anti-CD20 therapy in vivo uncovers spatiotemporal bottlenecks in antibody-dependent phagocytosis
Neutralizing antibody against anti–SARS-CoV-2 vaccination
Synergistic anti-tumor therapy by a comb-like multifunctional antibody nanoarray with exceptionally potent activity
Humoral- and T-Cell–Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies
Vaccines, Free Full-Text
Impact of Rituximab and Host/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20+ B Cell Malignancies - Biology of Blood and Marrow Transplantation
Building better monoclonal antibody-based therapeutics
Anti-CD20 monoclonal antibodies in Systemic Lupus Erythematosus - ScienceDirect
Frontiers Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?
Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis
Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies
Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review
Imaging the mechanisms of anti-CD20 therapy in vivo uncovers spatiotemporal bottlenecks in antibody-dependent phagocytosis
Anti-CD20 antibodies and bendamustine attenuate humoral immunity to COVID-19 vaccination in patients with B-cell non-Hodgkin lymphoma
Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: A meta-analysis - eBioMedicine
de
por adulto (o preço varia de acordo com o tamanho do grupo)
